Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Poster Session Abstracts

Abstract P4-08-05: Transfer of Trastuzumab® across the human placenta barrier

V Bjelic Radisic, MM Gruber, B Hirschmugl and C Wadsack
V Bjelic Radisic
Medical University Graz, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MM Gruber
Medical University Graz, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B Hirschmugl
Medical University Graz, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Wadsack
Medical University Graz, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.SABCS15-P4-08-05 Published February 2016
  • Article
  • Info & Metrics
Loading
Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX

Abstract

Background: Breast cancer (BC) occurs between one in 3000 to one in 10 000 pregnancies. About 20% to 44% of BC diagnosed in women younger than 30 ys is associated by Her2/Neu receptor overexpression. The prognosis of the Her2/Neu positive BC has improved fundamentally with the introduction of trastuzumab. The increasing age of child bearing mothers leads to an increased probability of the incidence of BC, and thus Her2/Neu positive BC in pregnancy as well.

The administration of trastuzumab during pregnancy is not recommended and leads to the development of reversible oligo- and anhydramnios and fetal renal volume. The mechanism has not been identified yet. Trastuzumab is a humanized monoclonal IgG kappa 1 antibody, which is transported across the human placenta. Moreover, the presence of Her2/Neu receptor in the second and third trimester placenta and fetal kidneys has been described. The interaction of trastuzumab with these tissues/receptors may cause the development of oligo- and anhydramnion. Apart of the study that tested the transplacental transfer of trastuzumab in pregnant baboon (2009), to our knowledge there are no data in the literature tested the transfer of trastuzumab across the human placenta.

Objectives: We examined the transfer of Trastuzumab® in a relevant pharmaceutical concentration across the human term placenta with the ex-vivo placenta perfusion model, as well as the expression of the Her2/Neu receptor in the placenta tissue (syncytiotrophoblast).

Methods: The dual ex vivo human placental perfusion model was used to analyse the transfer of Trastuzumab® across the placental barrier (n=3). The ex vivo placenta perfusion model was performed by establishing an artificial maternal and fetal circulation system within 20 minutes after delivery. Nutrition and oxygen supply was established to keep the tissue and its barrier function under physiological conditions over several hours. Closed loops of the maternal and fetal circulations were used within the perfusion experiments. We used an antibody concentration in the maternal circulation of 50 µg/ml. This concentration is a common bolus application in therapy of Her/2positive BC. Quantification of the protein was performed by ELISA. The presence of Her2/Neu in the placenta was determined by immunhistochemical stainings.

Results: The transport of Trastuzumab® in the maternal to fetal direction could not be detected over 90 minutes of placenta perfusion. An average antibody concentration decrease of about 30% was determined in the maternal circulation. The presence of the Her2/Neu receptor in the syncytiotrophoblast layer was detectable by immunhistochemical staining.

Conclusions: The results indicate that Trastuzumab® does not cross the human placenta within 90 min of placenta perfusion. Due to the presence of Her2/Neu receptor expression at the syncytiotrophoblast of the human placenta, a binding to this receptor is assumed. This may explain the trastuzumab decrease over time in maternal circulation. These findings indicate that the pregnancy complications can also be caused by a direct effect of trastuzumab on the human placenta. Our results are in contrast to published data of transplacental transfer of trastuzumab in pregnant baboon published 2009 and need to be investigated in further studies.

Citation Format: Bjelic Radisic V, Gruber MM, Hirschmugl B, Wadsack C. Transfer of Trastuzumab® across the human placenta barrier. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-08-05.

Previous
Back to top
Cancer Research: 76 (4 Supplement)
February 2016
Volume 76, Issue 4 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract P4-08-05: Transfer of Trastuzumab® across the human placenta barrier
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract P4-08-05: Transfer of Trastuzumab® across the human placenta barrier
V Bjelic Radisic, MM Gruber, B Hirschmugl and C Wadsack
Cancer Res February 15 2016 (76) (4 Supplement) P4-08-05; DOI: 10.1158/1538-7445.SABCS15-P4-08-05

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract P4-08-05: Transfer of Trastuzumab® across the human placenta barrier
V Bjelic Radisic, MM Gruber, B Hirschmugl and C Wadsack
Cancer Res February 15 2016 (76) (4 Supplement) P4-08-05; DOI: 10.1158/1538-7445.SABCS15-P4-08-05
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Session Abstracts

  • Abstract P6-01-01: Patterns of disease progression in patients with local and metastatic breast cancer as evaluated by whole-body MRI
  • Abstract P6-13-07: Chemotherapy with and without trastuzumab or no treatment in elderly patients with HER2 amplified breast cancer at a single center
  • Abstract P6-11-19: Efficacy and patient acceptability of the DigniCaP ScalpCooler to prevent hair loss in breast cancer patients receiving adjuvant chemotherapy
Show more 3

Tumor Cell and Molecular Biology: Cellular Mechanisms

  • Abstract P6-05-04: mRNA expression of PTK6V1 and PTKV2 in human breast cancer
  • Abstract P6-05-05: Discistronic reporter screen for internal ribosome entry site (IRES) - mediated translational regulation of truncated p110 ERBB2 isoform
  • Abstract P6-05-02: Targeting vesicular trafficking machinery for breast cancer therapeutics
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement